Literature DB >> 3082491

Referral of patients with cancer for participation in randomized clinical trials: ethical considerations.

R J Levine.   

Abstract

Physicians with patients with cancer may be faced with two conflicting ethical obligations. One is to contribute to the advancement of scientific knowledge. Among the ways available to respond to this duty is to refer patients for participation in RCTs. The second obligation is to serve the health interests of the individual patient. When these two duties conflict, the latter obligation to the individual takes priority. In the words of the Declaration of Helsinki, "Concern for the interests of the subject (patient) must always prevail over the interests of science and society." Quite often there is no conflict. The patient can pursue his or her health interests most effectively by enrollment in an RCT. In such cases, the referring physician can contribute to the success of the patient's participation in the RCT by explaining what the patient can expect to experience as a patient-subject. It is usually important to explain that referral does not necessarily entail severing the original doctor-patient relationship.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  1986        PMID: 3082491     DOI: 10.3322/canjclin.36.2.95

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  3 in total

1.  Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial.

Authors:  L J Fallowfield; A Hall; G P Maguire; M Baum
Journal:  BMJ       Date:  1990-09-22

2.  Clinical trials and physicians as double agents.

Authors:  R J Levine
Journal:  Yale J Biol Med       Date:  1992 Mar-Apr

3.  Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders.

Authors:  Primus Che Chi; Esther Awuor Owino; Irene Jao; Fredrick Olewe; Bernhards Ogutu; Philip Bejon; Melissa Kapulu; Dorcas Kamuya; Vicki Marsh
Journal:  Trials       Date:  2021-07-26       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.